Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
Open Access
- 22 March 2013
- journal article
- Published by Elsevier BV in Online Journal of Public Health Informatics
- Vol. 288 (12), 8279-8288
- https://doi.org/10.1074/jbc.m112.421370
Abstract
No abstract availableThis publication has 52 references indexed in Scilit:
- Effects of the Prosegment and pH on the Activity of PCSK9Online Journal of Public Health Informatics, 2010
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesProceedings of the National Academy of Sciences of the United States of America, 2009
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesProceedings of the National Academy of Sciences of the United States of America, 2008
- Molecular basis for LDL receptor recognition by PCSK9Proceedings of the National Academy of Sciences of the United States of America, 2008
- Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading ActivityBiochemistry, 2008
- Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound HeterozygoteAmerican Journal of Human Genetics, 2006
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseThe New England Journal of Medicine, 2006
- Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genesProceedings of the National Academy of Sciences of the United States of America, 2003
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences of the United States of America, 2003